Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Assets (2016 - 2025)

Iovance Biotherapeutics has reported Non-Current Assets over the past 13 years, most recently at $470.5 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $470.5 million for Q4 2025, up 3.77% from a year ago — trailing twelve months through Dec 2025 was $1.9 billion (changed 0.29% YoY), and the annual figure for FY2025 was $470.5 million, up 3.77%.
  • Non-Current Assets for Q4 2025 was $470.5 million at Iovance Biotherapeutics, down from $475.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for IOVA hit a ceiling of $484.9 million in Q2 2025 and a floor of $187.0 million in Q1 2023.
  • Median Non-Current Assets over the past 3 years was $471.5 million (2023), compared with a mean of $443.5 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 159.0% in 2024 and later dropped 6.24% in 2025.
  • Iovance Biotherapeutics' Non-Current Assets stood at $472.5 million in 2023, then dropped by 4.04% to $453.4 million in 2024, then rose by 3.77% to $470.5 million in 2025.
  • The last three reported values for Non-Current Assets were $470.5 million (Q4 2025), $475.9 million (Q3 2025), and $484.9 million (Q2 2025) per Business Quant data.